Overview

The Objective of This Study is to Compare the Oral Bioavailability and Characterize the Pharmacokinetic Profile

Status:
Completed
Trial end date:
2016-01-15
Target enrollment:
Participant gender:
Summary
Title of Study: An Open-Label, Balanced, Randomized, 2-Treatment, 2-Sequence, 2-Period, Single Dose, Crossover Oral Bioequivalence Study of Two Formulations of Fingolimod Capsules (3 x 0.5 mg) in Healthy Adult Human Subjects Under Fasting Conditions. Objective: The objective of this study is to compare the oral bioavailability and characterize the pharmacokinetic profile of the test formulation relative to that of reference formulation in healthy, adult, human subjects under fasting conditions and to assess the bioequivalence.
Phase:
Phase 1
Details
Lead Sponsor:
Alembic Pharmaceuticals Ltd.
Treatments:
Fingolimod Hydrochloride